

## CLAIMS

1.

N-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide ethanesulfonate.

2. A crystal of

N-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide ethanesulfonate.

3. The crystal according to claim 2, wherein in a powder X-ray diffraction spectrum, the crystal has peaks at  $2\theta$  of 7.3, 7.9, 9.1, 10.7, 11.2, 12.5, 13.4, 15.6, 16.2, 16.5, 17.7, 18.0, 18.4, 19.1, 20.1, 20.8, 21.2, 21.5, 22.4, 23.0, 23.6, and 24.0.

4. The crystal according to claim 2 or 3, having characteristics of the powder X-ray diffraction spectrum chart shown in FIG. 1.

5. The crystal according to claim 2 to 4, wherein in the differential scanning calorimetry, the crystal has an endothermic peak of an onset temperature of 283°C or a peak temperature of 286°C.

6. The crystal according to claim 2 to 5, having characteristics of the differential scanning calorimetry chart shown in FIG. 2.

7. A pharmaceutical composition comprising

N-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide ethanesulfonate or the crystal according to any one of claims 2 to 6, and a pharmaceutically acceptable carrier.

8. The pharmaceutical composition according to claim 7, which is an Axl inhibitor.

9. Use of the pharmaceutical composition according to claim 7 in the manufacture of an agent for the prevention and/or treatment of an Axl-related disease.

10. The use according to claim 9, wherein the Axl-related disease is cancer, an immune system disease, or a circulatory system disease.

11. The use according to claim 10, wherein the cancer is leukemia, malignant lymphoma, multiple myeloma, myelodysplastic syndromes, melanoma, uveal malignant melanoma, head and neck cancer, esophageal cancer, esophageal adenocarcinoma, stomach cancer, large intestine cancer, colon cancer, rectal cancer, liver cancer, gallbladder and bile duct cancer, biliary tract cancer, pancreatic cancer, thyroid cancer, lung cancer, breast cancer, ovarian cancer, cervical cancer, uterine body cancer, endometrial cancer, vaginal cancer, vulvar cancer, renal cell carcinoma, urothelial carcinoma, prostate cancer, testicular tumor, bone and soft tissue sarcoma, skin cancer, glioma, brain tumors, pleural mesothelioma or cancer of unknown primary.

12. An agent for use in the prevention and/or treatment of an Axl-related disease, the agent comprising

N-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide ethanesulfonate or the crystal according to any one of claims 2 to 6.

13. The use according to claim 12, wherein the Axl-related disease is cancer, an immune system disease, or a circulatory system disease.

14. The use according to claim 13, wherein the cancer is leukemia, malignant lymphoma, multiple myeloma, myelodysplastic syndromes, melanoma, uveal malignant melanoma, head and neck cancer, esophageal cancer, esophageal adenocarcinoma, stomach cancer, large intestine cancer, colon cancer, rectal cancer, liver cancer, gallbladder and bile duct cancer, biliary tract cancer, pancreatic cancer, thyroid cancer, lung cancer, breast cancer, ovarian cancer, cervical cancer, uterine body cancer, endometrial cancer, vaginal cancer, vulvar cancer, renal cell carcinoma, urothelial carcinoma, prostate cancer, testicular

tumor, bone and soft tissue sarcoma, skin cancer, glioma, brain tumors, pleural mesothelioma or cancer of unknown primary.